Following independent studies, using JQ1 to target BRD4 and SEs, have demonstrated similar effects in a broad spectrum of cancer types, such as colorectal cancer (126), ovarian cancer (127), Merkel cell carcinoma (128), B cell lymphoma (129), and alveolar rhabdomyosarcoma (123). This evidence concerns the gene BRD4 and cancer.